Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 9/20 | 0.68 |
| ▸ | CA12 | O43570 | 8/20 | 0.68 |
| ▸ | CA1 | P00915 | 7/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.67 |
| ▸ | RAB9A | P51151 | 3/20 | 0.67 |
| ▸ | NPC1 | O15118 | 2/20 | 0.67 |
| ▸ | TSHR | P16473 | 2/20 | 0.67 |
| ▸ | CASP1 | P29466 | 2/20 | 0.67 |
| ▸ | CASP7 | P55210 | 1/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.67 |
| ▸ | CA2 | P00918 | 4/20 | 0.66 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.66 |
| ▸ | CA4 | P22748 | 3/20 | 0.62 |
| ▸ | MEN1 | O00255 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | GFER | P55789 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | PPARA | Q07869 | 1/20 | 0.56 |
| ▸ | CA7 | P43166 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4234750 | 0.87 | CA9 (0.77) | CA9CA12CA1ALDH1A1RAB9A | |
| SCHEMBL8995319 | 0.87 | CASP1 (0.86) | CA9CA12CA1ALDH1A1RAB9A | |
| SCHEMBL16790049 | 0.86 | CA9 (0.63) | CA9CA12CA1CA2SCN2A | |
| SCHEMBL9339007 | 0.85 | CA9 (0.77) | CA9CA12CA1ALDH1A1RAB9A | |
| SCHEMBL9566650 | 0.85 | CASP1 (0.83) | CA9CA12CA1ALDH1A1RAB9A | |
| SCHEMBL4230568 | 0.84 | TYMS (0.61) | CA9CA1ALDH1A1RAB9ANPC1 | |
| SCHEMBL23775707 | 0.83 | MEN1 (0.81) | CA9CA12CA1ALDH1A1RAB9A | |
| SCHEMBL15614030 | 0.83 | CA9 (0.61) | CA9CA12CA1ALDH1A1RAB9A | |
| SCHEMBL8310927 | 0.83 | ALDH1A1 (0.59) | CA9CA12CA1ALDH1A1RAB9A | |
| SCHEMBL7197151 | 0.83 | ESR1 (0.75) | CA9CA12CA1CA2SCN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215814-A1 | Method of inhibiting neurotrophin-receptor binding | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2009-08-27 | — | — | US | disclosed |
| US-20070078137-A1 | Method of inhibiting neurotrophin-receptor binding | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2007-04-05 | — | — | US | disclosed |
| US-7148352-B2 | Method of inhibiting neurotrophin-receptor binding | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2006-12-12 | — | — | US | disclosed |
| US-20030186901-A1 | Method of inhibiting neurotrophin-receptor binding | MINE SAFETY APPLIANCES COMPANY | 2003-10-02 | — | — | US | disclosed |
| US-6468990-B1 | ADMINISTERING COMPOUNDS HAVING ELECTRONEGATIVE GROUPS WHICH INTERACT WITH CERTAIN LYSINE RESIDUES IN NERVE GROWTH FACTOR AND/OR HYDROPHOBIC MOIETY WHICH INTERACTS WITH HYDROPHOBIC REGION FORMED BY CERTAIN ISOLEUCINE AND PHENYLALANINE RESIDUES | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2002-10-22 | — | — | US | disclosed |
| EP-1226121-A1 | METHOD OF INHIBITING NEUROTROPHIN-RECEPTOR BINDING | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2002-07-31 | — | — | EP | disclosed |
| WO-2000069829-A1 | METHOD OF INHIBITING NEUROTROPHIN-RECEPTOR BINDING | QUEEN'S UNIVERSITY (CA) | 2000-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215814-A1 | Method of inhibiting neurotrophin-receptor binding | NGF, NTRK2, BDNF | CA9 3655/4885CA12 2567/4885CA1 1178/4885 |
| US-20070078137-A1 | Method of inhibiting neurotrophin-receptor binding | NGF, NTRK2, BDNF | CA9 3655/4885CA12 2567/4885CA1 1178/4885 |
| US-20030186901-A1 | Method of inhibiting neurotrophin-receptor binding | NGF, NTRK2, BDNF | CA9 4005/4885CA12 2650/4885CA1 1142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.